Table 1 Baseline characteristics of GC patients from public databases in this study
Cohorts | TCGA (N = 375) | GSE84437 (N = 433) | GSE66229 (N = 300) | GSE15459 (N = 191) | GSE26253 (N = 432) | GSE26942 (N = 202) | Kim cohort (N = 45) |
|---|---|---|---|---|---|---|---|
Survival status | |||||||
 Alive | 224 (59.7%) | 224 (51.7%) | 148 (49.3%) | 96 (50.3%) | 265 (61.3%) | 114 (56.4%) | / |
 Dead | 150 (40.0%) | 209 (48.3%) | 152 (50.7%) | 95 (49.7%) | 167 (38.7%) | 88 (43.6%) | / |
 NA | 1 (0.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | / |
Gender | |||||||
 Female | 134 (35.7%) | 137 (31.6%) | 101 (33.7%) | 67 (35.1%) | 152 (35.2%) | 60 (29.7%) | / |
 Male | 241 (64.3%) | 296 (68.4%) | 199 (66.3%) | 124 (64.9%) | 280 (64.8%) | 142 (70.3%) | / |
Age | |||||||
  < 56 | 63 (16.8%) | 144 (33.3%) | 76 (25.3%) | 43 (22.5%) | 253 (58.6%) | 90 (44.6%) | / |
  >  = 56 | 308 (82.1%) | 289 (66.7%) | 224 (74.7%) | 148 (77.5%) | 179 (41.4%) | 112 (55.4%) | / |
 NA | 4 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | / |
Stage | |||||||
 I | 53 (14.1%) | 18 (4.2%) | 30 (10.0%) | 31 (16.2%) | 68 (15.7%) | 51 (25.2%) | 0 (0%) |
 II | 111 (29.6%) | 206 (47.6%) | 97 (32.3%) | 29 (15.2%) | 167 (38.7%) | 36 (17.8%) | 0 (0%) |
 III | 150 (40.0%) | 209 (48.2%) | 96 (32.0%) | 72 (37.7%) | 130 (30.1%) | 63 (31.3%) | 0 (0%) |
 IV | 38 (10.1%) | 0 (0%) | 77 (25.7%) | 59 (30.9%) | 67 (15.5%) | 51 (25.2%) | 45 (100.0%) |
 NA | 23 (6.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.5%) | 0 (0%) |
Lauren classification | |||||||
 Diffuse | / | / | 135 (45.0%) | 75 (39.3%) | / | 42 (20.8%) | / |
 Intestinal | / | / | 146 (48.7%) | 98 (51.3%) | / | 141 (69.8%) | / |
 Mixed | / | / | 19 (6.3%) | 18 (9.4%) | / | 7 (3.5%) | / |
 NA | / | / | 0 (0%) | 0 (0%) | / | 12 (5.9%) | / |
Stage T | |||||||
 T1 | 19 (5.1%) | 11 (2.5%) | 0 (0%) | / | / | / | / |
 T2 | 80 (21.3%) | 38 (8.8%) | 186 (62.0%) | / | / | / | / |
 T3 | 168 (44.8%) | 92 (21.2%) | 91 (30.3%) | / | / | / | / |
 T4 | 100 (26.7%) | 292 (67.5%) | 21 (7.0%) | / | / | / | / |
 Tx | 8 (2.1) | 0 (0%) | 2 (0.7%) | / | / | / | / |
Stage N | |||||||
 N0 | 111 (29.6%) | 80 (18.5%) | 38 (12.7%) | / | / | / | / |
 N1 | 97 (25.9%) | 188 (43.4%) | 131 (43.6%) | / | / | / | / |
 N2 | 75 (20.0%) | 132 (30.5%) | 80 (26.7%) | / | / | / | / |
 N3 | 74 (19.7%) | 33 (7.6%) | 51 (17.0%) | / | / | / | / |
 Nx | 18 (4.8%) | 0 (0%) | 0 (0%) | / | / | / | / |
Stage M | |||||||
 M0 | 330 (88.0%) | 433 (100.0%) | 273 (91.0%) | / | / | 187 (92.6%) | 0 (0%) |
 M1 | 25 (6.7%) | 0 (0%) | 27 (9.0%) | / | / | 14 (6.9%) | 45 (100.0%) |
 Mx | 20 (5.3%) | 0 (0%) | 0 (0%) | / | / | 1 (0.5%) | 0 (0%) |
Chemotherapy | |||||||
 Yes | / | / | / | / | 432 (100.0%) | 106 (52.5%) | / |
 No | / | / | / | / | 0 (0%) | 96 (47.5%) | / |
Overall response (immunotherapy) | |||||||
 CR | / | / | / | / | / | / | 3 (6.7%) |
 PR | / | / | / | / | / | / | 9 (20.0%) |
 SD | / | / | / | / | / | / | 15 (33.3%) |
 PD | / | / | / | / | / | / | 18 (40.0%) |